Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 18/20 | 0.66 |
| ▸ | STAT6 | P42226 | 1/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239707 | 0.82 | SLC29A1 (0.56) | SLC29A1STAT6PDE4APDE4BPDE4C | |
| SCHEMBL27427587 | 0.80 | SLC29A1 (0.76) | SLC29A1STAT6PDE4APDE4BPDE4C | |
| SCHEMBL13239706 | 0.80 | ADORA3 (0.66) | SLC29A1 | |
| 6-Benzylthioinosine SCHEMBL7617372 | 0.80 | SLC29A1 (1.00) | SLC29A1STAT6 | |
| 6-Benzylthioinosine SCHEMBL15427008 | 0.80 | SLC29A1 (1.00) | SLC29A1STAT6 | |
| 6-Benzylthioinosine SCHEMBL7617380 | 0.80 | SLC29A1 (1.00) | SLC29A1STAT6 | |
| 6-Benzylthioinosine SCHEMBL3676029 | 0.80 | SLC29A1 (1.00) | SLC29A1STAT6 | |
| SCHEMBL14030778 | 0.78 | TYMP (0.47) | SLC29A1STAT6PDE4APDE4BPDE4C | |
| SCHEMBL14030794 | 0.77 | EHMT1 (0.43) | SLC29A1STAT6 | |
| SCHEMBL13449217 | 0.76 | ADORA3 (0.59) | SLC29A1STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501931-B2 | Convertible nucleoside derivatives | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2013-08-06 | — | — | US | disclosed |
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | LAKSHMAN MAHESH K | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | PNP, NUDT1, NUDT14 | SLC29A1 19/4885STAT6 4656/4885PDE4A 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.